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As with other members of the herpesvirus group, cytomegaloviruses (CMV)'
do not seriously harm the immunocompetent host, but establish latent infection.
Congenital CMV infection, however, is responsible for severe neurological dis-
orders in immunologically immature newborns (1), and, by causing interstitial
pneumonia, opportunistic primary or recurrent CMV infection is an often fatal
complication in bone marrow transplant recipients after iatrogenic immuno-
suppression (2). More recently, CMV disease has been diagnosed as one of the
leading immediate causes of death in acquired immunodeficiency syndrome
(AIDS) victimsimmunocompromised by infection with human immunodeficiency
virus (HIV) (3). Experimental infection with murine CMV (MCMV) of immu-
nodeficient in comparison with immunocompetent or reconstituted mice has
proven a valid model system for studying CMV pathogenesis (4-6), and has
indicated a role for the cytolytic, CD8 (Lyt-2)-positive subset of T lymphocytes
(CTL) in controlling CMV infection (6, 7).
In aprevious communication (6) we have described an adoptive transfer model
for the immunotherapy of established CMV infection, characterized by the
following conditions: (a) in the immunocompetent BALB/c mouse, replication
of MCMV is restricted to glandular epithelial cells in the acini of the salivary
glands; (b) after immunodepletion by total-body y irradiation, MCMV replicates
in various tissues, including lung tissue; (c) viral genome can be detected in cells
of the alveolar septa 6 d after intraplantar infection; (d) an antiviral effect in
immunodepleted transfer recipients is mediated by sensitized CD8 (Lyt-2)-posi-
tive T lymphocytes derived directly from draining popliteal donor lymph nodes,
while CD4 (L3T4)-positive lymphocytes are neither efficient nor necessary; (e)
the CD8 effector cells can be applied therapeutically after MCMV has colonized
lung tissue.
In recent studies and clinical trials interleukin 2 (IL-2) has proven an effective
means to enhance the efficacy of antitumor immunotherapy (for review see 8-
10). The prospects for an IL-2-supported immunotherapy ofan established viral
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infection depend on the pathobiology of the agent with particular respect to
target tissues, cytopathogenicity, and speed of virus spreading.
For the immunotherapy ofan established MCMV infection in the immunocom-
promised natural host, our data demonstrate that application of IL-2 in vivo can
significantly improve the control of virus multiplication .
Materials and Methods
Adoptive Transfer.
￿
Lymphocyte transfer was performed essentially as described previ-
ously (6) with the modification that cells were given intraperitoneally (i.p.). In brief,
sensitized lymphocytes derived from draining popliteal lymph nodes ofimmunocompetent
BALB/c donors 8 d after intraplantar infection with 105 PFU of MCMV (strain Smith,
VR-194; American Type Culture Collection, Rockville, MD) were transferred into the
peritoneal cavity of BALB/c recipients infected in the footpad with the same dose of
MCMV after immunodepletion by total-body y irradiation with 6 Gy. Depletion of donor
lymphocytes for CD8+ and CD4' cells was achieved by treatment with monoclonal
antibodies anti-Lyt-2.2 (hybridoma 19/178) and anti-L3T4 (GK 1 .5), respectively, and
complement (6).
Tissue Virus Titers.
￿
Infectious MCMV in the indicated tissues was quantitated 14 d
postinfection, as described previously (6). The detection limit of the plaque assay was 50
PFU of MCMV per organ homogenate. The pooled parotid, greater sublingual, and
mandibular glands are collectively referred to as salivary glands. Sets of virus titers are
regarded as significantly different for p < a = 0.05 (one-sided), where p denotes the
observed probability value, and a denotes the selected significance level (Wilcoxon-Mann-
Whitney exact rank sum test).
Recombinant Human IL-2 (MIL-2). rhIL-2 was generously supplied by the Sandoz
Forschungsinstitut, Vienna, Austria. Lot 89050/84802 is >99% pure IL-2 (1 .04 ± 0 .35
ng of LPS per milligram of protein) with a specific activity of 7 .3 X 106 U/mg of protein
normalized to a reference standard (lot LSP-841) supplied by the Biological Resources
Branch at the National Cancer Institute, Frederick, MD. Bioavailability of rhIL-2 was
controlled with an IL-2-dependent subline of the BALB/c-derived T helper line HT-2.
Cells were recovered from the peritoneal cavity of immunodepleted recipients 4 d after
i.p. transfer of 10' HT-2, and the number of viable clone-forming HT-2 was determined
in a limiting-dilution assay. With no IL-2 added in vivo, only 1420 (95% confidence
interval: 930-2150) HT-2 could be recovered (0.014%), while i.p. administrations of 10'
U (1 .37 jig, 880 pmol) of rhIL-2 in 12-h intervals for 4 d yielded 3 .3 (2.4 - 4.6) X 10'
HT-2, indicating proliferation in vivo. Lower doses of IL-2 or longer intervals between
the IL-2 applications were less effective, and a gelatin depot did not improve the recovery.
Therefore, the experiments were performed with 10' U of rhIL-2 in 0.5 ml of 0.15 M
NaCl administered i.p. in 12-h intervals.
Results and Discussion
Application of rhIL-2 In Vivo Improves Immunoprophylaxis and Immunotherapy of
MCMV Disease. In an immunocompromised but not completely immunodefi-
cient host, a limited number of sensitized lymphocytes may still be present,
though not sufficient in quantity to cope with CMV infection. In the murine
model system, adoptive transfer allows study of the antiviral potential of a
defined, limited number of lymphocytes, and allows evaluation of the prospects
for enhancing this potential. Prophylactic (Fig. 1) and therapeutic (Fig. 2) transfer
models (6) mimic two different clinical conditions in the immunocompromised
host. In the first case, virus has not yet colonized tissue, and protective immunity
may operate by preventing this. In the second case, virus is already present in
tissues and protective immunity has to counteract the progression of established652
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FIGURE 1 .
￿
Preventive treatment for CMV disease by prophylactic adoptive transfer. The
treatmentperiod was started2hafterintraplantar infection of eightimmunodepleted BALB/c
mice per experimental group (prophylaxis). Closed circles represent the virus titers in the
indicated organs of individual recipients determined at day 14 postinfection. The median
values of thevirus titers aremarked by horizontal bars. Thedashed line indicates thedetection
limit. (A) No transfer of lymphocytes. (B) Transfer of 50,000 sensitized donor lymphocytes
(defined as one unit dose) at day 0. (C) Transfer of 16 unit doses at day 0. (D) Repetitive
transfer of one, one, two, four, andeight unit doses in 24 h intervalsat days 0, 1, 2, 3, and 4,
respectively (arrows). (E) Transfer of one unit dose of sensitized donor lymphocytes at day 0
supported by eight subsequent applications of rhIL-2 (10' U each) in 12-h intervals (arrow-
heads), thefirst of which wasgiven along with the lymphocytes.
infection. During acute MCMV infection of immunodepleted BALB/c mice,
virus has colonized target tissues by day 6 postinfection, as hasbeen demonstrated
by detectionofthe viral genome in various cell types ofthe lungs (6),and likewise
also in reticular cells ofthe spleen, hepatocytes ofthe liver, parenchymal cells in
the reticular and fascicular zones of the adrenal gland cortex, and secretory as
well as connective tissue cells ofthe salivary glands (K. Münch and F. Weiland,
personal communication). Transfer of lymphocytes at that stage of infection can
therefore be regarded as a therapeutic regimen.
The idea in our experiments (Figs. I and 2) was to augment the function ofa
defined, insufficient number of lymphocytes (compare columns B and B' with
the respective columns A, Figs. I and 2) by in vivo application of rhIL-2 under
conditions that exclude recruitment ofrecipient lymphocytes. With the assump-
tion that IL-2 in vivo maintains growth and functional activity of transferred7,
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FIGURE 2.
￿
Treatment of established tissue infection by therapeutic adoptive transfer. The
treatment period wasstarted 6 d after intraplantarinfection of eight immunodepleted BALB/c
mice per experimental group at a time when MCMV has colonized target tissue (6). Controls
that have not received lymphocyteswere the same individuals as in Fig. 1 (A). The experimental
schedulesB'-E' correspond to that of the prophylactic regimen (Fig. 1 ; B-E), except that the
unit dose of transferred cells was 10-fold.
donor lymphocytes, and that the lymphokine thereby supports one effector
population doubling per day, the total number of cells generated during a 4-d
period would be 16-fold. This amount of effector cells is effective in controlling
virus multiplication when given in a single dose on the first day of the treatment
period, depending in efficacy on the time of transfer and the site of virus
multiplication (columns C and C', Figs. 1 and 2). During IL-2-mediated augmen-
tation, however, this high amount of effector cells is not available at once, but is
generated, with delay, at a speed determined by the generation time of the
lymphocytes, with the consequence that increasing cell numbers have to cope
with infection in progressing stages. Such a condition was simulated by repetitive
transfer of sensitized lymphocytes in daily intervals and resulted in intermediate
tissue virus titers (columns D and D'). Repeated application of rhIL-2 (columns
E and E') indeed significantly enhanced the antiviral effect of the low initial
number of lymphocytes in several tissues in prophylaxis and, except for the
adrenal glands, also in therapy [lungs: p(BE) = 0 .005, p(B'E') < 0.001 ; spleen:
p(BE) < 0.005, p(B'E') < 0.001 ; adrenal glands: p(BE) < 0.005, p(B'E') > 0 .1] .
This result is consistent with the assumption of one population doubling per day,654
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as approximately the same antiviral effects were observed when lymphocyte
proliferation was simulated by repetitive lymphocyte transfer (compare columns
D and D' with E and E', respectively, Figs. 1 and 2). Regardless of whether
support of cell proliferation was the only effect of IL-2, the data demonstrate
that the net effect of IL-2 was equivalent to one effector population doubling
per day.
Site-specific Differences in Antiviral Efficacy ofProphylactic and Therapeutic Lym-
phocyte Transfer. Antiviral lymphocytes proved to be effective in the prophylac-
tic control of infection in the lungs and the spleen and, provided higher cell
numbers were transferred, treatment was effective also during established infec-
tion of those organs (Figs. 1 and 2). Consistent with the fact that salivary gland
tissue is a preferred site of MCMV replication in the immunocompetent host (6),
virus multiplication in salivary glands was only moderately affected [Fig. 1, p(AC)
< 0.005; Fig. 2, p(AC') = 0.1]. Because MCMV always colonized the salivary
glands, the protection observed for other tissues was not caused by prevention
of virus spreading from the plantar site of infection. Transferred lymphocytes
confined MCMV replication in the salivary glands to glandular epithelial cells,
while in the immunodepleted host, infection expands to connective tissue fibro-
blasts (F. Weiland, manuscript in preparation), indicating cell-type-specific rather
than organ-specific reasons for the preferred role of the salivary glands in CMV
infection. The property of adoptively transferred donor-type T lymphocytes to
distribute widely and persist long-term in the recipient has been demonstrated
in another model system (11).
MCMV adrenalitis has been described recently for T cell-deficient nu/numice
(12), and adrenal necrosis is one symptom of AIDS (1-3). Considering the life-
threatening consequences of adrenal cortical dysfunction, it is worth noting that
infection of that gland could be prevented only when high numbers of lympho-
cytes were available at an early stage of infection (Fig. 1, column C), while
repetitive transfer as well as IL-2-supported prophylactic treatment failed to
protect from adrenal infection in five of seven (Fig. 1, column D) and in six of
six (Fig. 1, column E) recipients, respectively. Accordingly, MCMV multiplication
could only moderately be inhibited during established adrenalitis (Fig. 2, column
C') . Whether in the adrenal gland cortex the hormonal environment suppresses
protective immunity remains to be investigated.
Identification ofIL-2-responsive Antiviral Effector Cells.
￿
The control of MCMV
infection has previously been assigned to the CD8 (Lyt-2)-positive T lymphocyte
subset (6). This, together with the known function of IL-2 to mediate prolifera-
tion of that subset, strongly suggested that CD8' antiviral T lymphocytes are the
targets of the IL-2 effect observed. To confirm this, alternatives had to be
excluded (Fig. 3). Application of rhIL-2 alone did not limit virus multiplication
(Fig. 3 A; p > 0.1). Thus, IL-2 by itself had no antiviral effect, nor did it recruit
putative residual lymphocytes in the irradiated host. IL-2 also failed to elicit
antiviral effectors from transferred nonprimed lymphocytes (B; p > 0.1). This
result excluded a significant participation of in vivo-generated lymphokine-
activated killer (LAK) cells (8). Sensitized lymphocytes depleted of CD4 (L3T4)-
positive lymphocytes contained the IL-2-responsive antiviral effectors (C; p =3-
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FIGURE 3 .
￿
IL-2 enhances the antiviral effect of CD8+lymphocytes in vivo. Virus titers in the
spleen were determined at day 14 postinfection after therapeutic transfer at day 6 postinfection
of 5 x 105 lymphocytes with no rhIL-2 (-IL-2) or with rhIL-2 administered according to the
schedule shown in Fig. 2 (IL-2+). (A) No transfer of lymphocytes. (B) Transfer of lymphocytes
derived from popliteal lymph nodes of noninfected donors. (C) Transfer of sensitized lympho-
cytes depleted of CD4 (L3T4}positive lymphocytes. (D) Transfer of sensitized lymphocytes
depleted of CD8 (Lyt-2.2}positive lymphocytes.
0.001), while CD8+ populations made up of CD4+ (T helper) lymphocytes and
accessory cells were not effective (Fig. 3D; p > 0.1).
Predictions Deduced from the Model System.
￿
IL-2 has been demonstrated pre-
viously to enhance in vitro the CMV-specific cytolytic activity of lymphocytes
isolated from AIDS patients (14), indicating the existence of a residual, IL-2-
responsive antiviral CD8+ population. Our results in a model system predict that
the effect of a limited number of antiviral effectors can be enhanced by applica-
tionofIL-2 also in vivo. While an immunotherapy ofinterstitial CMV pneumonia
might have some chance, the prospects for controlling established CMV infection
of the adrenal glands appear to be less promising.
Summary
We have shown in a murine model system for cytomegalovirus (CMV) disease
in the immunocompromised host that in vivo application of recombinant human
IL-2 (rhIL-2) can enhance the antiviral effect of a limited number of CD8+ T
lymphocytes, not only in prophylaxis, but also in therapy, when virus has already
colonized host tissues. The observed net effect of IL-2 was consistent with the
assumption of daily effector population doublings. The prospects for IL-2-
supported immunotherapy ofestablished CMV infection depend upon the tissues
involved in disease. It appears that theprospects forcontrolling established CMV
adrenalitis are less promising than for a therapy of interstitial CMV pneumonia.
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